Biopharmaceutical Company, Windtree Therapeutics, Inc, based in Warrington, Pennsylvania. announced that as of August 21, 2025, it will suspend the contribution of its stock in the NASDAQ capital markets.
This decision occurred after notification of the US stock market itself and decided to exempt from repeated violations of contribution standard 5550(a)(2) related to the lowest price of the stock.
It’s worth clarifying The expulsion has nothing to do with the company’s business. It’s as it reported it – Focus on BNB accumulation and stakingcryptocurrency created by Exchange Binance.
As a result, the decision of the Nasdaq Windley Common Stockidentified by Wint symbol, They will be negotiated in markets outside of thrill (For OTC, English acronyms), especially on the OTCID platform, the company had already submitted requests. However, we warned that there is no guarantee that such an application has been approved.
After these novelties, Wint’s prices fell by more than 70% in a few minutes, as can be seen in the next TradingView graph.
The company emphasized that changes to its contribution platform will not affect its operations or business model. The statement signed by President and Executive Director Jed Rutkin also included a preventive statement on future forecasts. The company emphasized that despite the orderly transition to the OTC market, external and internal factors could affect the outcome and acceptance of titles in that market.
The suspension of NASDAQ prices and the relocation to the OTC market marks a new chapter in Windree Therapeutics.
